Authors
Linlin Cao, Yifan Chen, Wei Zhang, Huiru Jiang, Honghao Huang, Yudian Xu, Xi Li, Wei Xu, Kun Qian, Jun Pu
Published in
Science translational medicine. Volume 18. Issue 871. Pages eadz4815. Oct 14, 2026. Epub Oct 14, 2026.
Abstract
Aging is characterized by progressive functional decline, yet metabolomic signatures across the human life span remain incompletely defined. Here, we profiled plasma metabolomes from 18,476 participants aged 1 to 96 years across six centers in China using nano-assisted laser desorption/ionization mass spectrometry (LDI-MS) and identified 56 representative age-associated metabolites. In a healthy cohort, we developed a stacking ensemble model to estimate metabolomic age and quantified metabolomic age acceleration (mAA) as each individual's deviation from chronological age. Higher mAA was associated with health deterioration and unfavorable lifestyles. During follow-up from 2019 to 2025, individuals with accelerated mAA showed increased risk of incident chronic diseases, such as fatty liver disease, hypertension, and diabetes, as well as increased all-cause mortality. In a disease cohort, we further developed a mortality-linked metabolomic metric (age deviation) that quantified individualized departures from age-expected mortality risk inferred from plasma metabolites. Age deviation was associated with established composite health measures and increased with multisystem disease involvement and higher multimorbidity burden. Together, these findings support the potential of plasma metabolomic profiling as a scalable, life span-wide approach for deriving clinically interpretable metabolomic aging metrics associated with health status, chronic disease risk, and mortality.
PMID:
42873893
Bibliographic data and abstract were imported from PubMed on 15 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 45
- Comments 0